Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
ABC
DEL
DHL
DLBCL
GCB
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
19
10
2022
received:
09
08
2022
accepted:
22
10
2022
pubmed:
29
10
2022
medline:
3
2
2023
entrez:
28
10
2022
Statut:
ppublish
Résumé
Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R-CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well-characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non-GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI
Identifiants
pubmed: 36305717
doi: 10.1002/hon.3098
pmc: PMC10037910
mid: NIHMS1865556
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-49Subventions
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097274
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA195568
Pays : United States
Informations de copyright
© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Références
J Clin Oncol. 2011 Nov 1;29(31):4079-87
pubmed: 21947824
Haematologica. 2018 Feb;103(2):288-296
pubmed: 29097500
Br J Haematol. 2020 Apr;189(2):313-317
pubmed: 31804715
J Clin Oncol. 2011 Jan 10;29(2):200-7
pubmed: 21135273
J Clin Oncol. 2017 Aug 1;35(22):2515-2526
pubmed: 28525305
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Cancer Cell. 2021 Oct 11;39(10):1422-1437.e10
pubmed: 34597589
Hematol Oncol. 2023 Feb;41(1):39-49
pubmed: 36305717
Blood. 2012 May 17;119(20):4619-24
pubmed: 22408263
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
Blood Cancer J. 2020 Nov 9;10(11):117
pubmed: 33168821
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Blood. 2005 Nov 15;106(10):3383-5
pubmed: 16091454
Lancet. 2013 May 25;381(9880):1817-26
pubmed: 23615461
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
Blood. 2013 May 16;121(20):4021-31; quiz 4250
pubmed: 23449635
J Clin Oncol. 2017 Jan;35(1):24-31
pubmed: 28034071
Cancer Cell. 2011 Dec 13;20(6):728-40
pubmed: 22137796
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
Blood. 2015 Nov 26;126(22):2466-74
pubmed: 26373676
Leukemia. 2012 Sep;26(9):2103-13
pubmed: 22437443
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Lancet Haematol. 2020 Jul;7(7):e511-e522
pubmed: 32589977
Lancet Oncol. 2020 Jul;21(7):978-988
pubmed: 32511983
Blood. 2010 Dec 2;116(23):4916-25
pubmed: 20736456
Nat Rev Clin Oncol. 2019 Oct;16(10):634-652
pubmed: 31127191
Br J Haematol. 2017 Oct;179(1):50-60
pubmed: 28653407
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
Int J Epidemiol. 2017 Dec 1;46(6):1753-1754i
pubmed: 29025017
Am J Hematol. 2021 May 1;96(5):599-605
pubmed: 33661547
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
J Clin Oncol. 2012 Dec 20;30(36):4462-9
pubmed: 23091101